CIK 1715579
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Unclassified | 89.48% | 2 |
| Pharmaceuticals & Biotechnology | 10.52% | 2 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | CENTESSA PHARMACEUTICALS PLC | Unclassified | 80.76% | |
| 2 | NAMS | NEWAMSTERDAM PHARMA COMPANY | Unclassified | 8.72% |
| 3 | PHAT | Phathom Pharmaceuticals, Inc. | Health Care | 8.45% |
| 4 | AURA | Aura Biosciences, Inc. | Health Care | 2.07% |
2/4 names classified · sector 10.5% of weight · industry 10.5% · mkt cap 10.5%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 10.5% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/4 names) · unclassified 100.0%: , NAMS, PHAT, AURA. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| CENTESSA PHARMACEUTICALS PLC | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | 20.0M | $793M |
| NAMSNEWAMSTERDAM PHARMA COMPANY | 2.9M | 2.9M | 2.9M | 2.9M | 2.9M | 2.7M | $86M |
| PHATPHATHOM PHARMACEUTICALS INC | 7.5M | 7.5M | 7.5M | 7.5M | 7.5M | 7.5M | $83M |
| AURAAURA BIOSCIENCES INC | 3.0M | 3.0M | 3.0M | 3.0M | 3.0M | 3.0M | $20M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
